Update the "Rational design of multivalent nanoparticle-pMHC-II immunotherapies for food allergen tolerance induction in eosinophilic esophagitis" manuscript based on the newly refined scientific plan and business plan to ensure alignment across all strategic documents.

This session aimed to update the "Rational design of multivalent nanoparticle-pMHC-II immunotherapies for food allergen tolerance induction in eosinophilic esophagitis" manuscript so that it aligned with a newly refined scientific plan and business plan.

The agent revised the manuscript and its supplemental materials toward a "personalized" framing of the pMHC-II therapeutic approach, producing updated main text and supplement documents along with a markdown version of the manuscript. Supporting work included compiling a candidate pMHC-II list, generating a figure of a "personalization engine," and tracking changes and reference/reconciliation data to document how the revision was carried out. No final agent message was recorded, so the specific narrative of conclusions or decisions made during the session is not available from the provided metadata.

The primary deliverables are the revised manuscript files (EoE_manuscript_personalized.docx, EoE_manuscript_personalized.md, and EoE_manuscript_personalized_supplemental.docx), supported by fig_personalization_engine.png and the pmhc_ii_candidates_msw.csv candidate data table. Process/tracking artifacts—manuscript_changelog.md, manuscript_reconciliation.csv, manuscript_references.csv, and a repositioning plan JSON—document the alignment work but contain no additional results beyond what's listed.